Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Med Res Rev. 2018 Mar 12;38(6):1769–1798. doi: 10.1002/med.21496

Figure III. Clinical trials of anti-angiogenic chemotherapy and anti-lymphangiogenic chemotherapy.

Figure III

An advanced search of NIH U.S National Library of Medicine ClinicalTrials.gov shows a steady approval rate of clinical trials for anti-angiogenic therapies. In contrast, clinical trials for therapies targeting lymphangiogenesis are sparse. The only observable approvals of anti-lymphangiogenic therapies occurred in 2005 and 2010, with less than 10 approvals in total. While the number of anti-angiogenic chemotherapies approved in 2008 was well beyond 40, the number of anti-lymphangiogenic therapies was far fewer.